Asset Details
Do you wish to reserve the book?
Progress report of a cross‐organ and biomarker‐based basket‐type clinical trial: BELIEVE Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Progress report of a cross‐organ and biomarker‐based basket‐type clinical trial: BELIEVE Trial
Do you wish to request the book?
Progress report of a cross‐organ and biomarker‐based basket‐type clinical trial: BELIEVE Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Progress report of a cross‐organ and biomarker‐based basket‐type clinical trial: BELIEVE Trial
2024
Overview
Cancer genomic medicine using next‐generation sequencers has been developing. However, the number of patients who could receive genomically matched therapy is limited because off‐label use or patient‐oriented compassionate use was not permitted under National Health Insurance in Japan. To improve patient drug accessibility, we initiated a biomarker‐based basket‐type clinical trial (NCCH1901) in October 2019 under patient‐proposed healthcare services. We listed the drugs that had high medical needs but were not covered by National Healthcare Insurance. Then we included these drugs before patient proposal so that they could access off‐label drugs soon after they had the results of CGP tests. All drugs were provided free of charge by pharmaceutical companies. The objective was to administer off‐label drugs and to collect efficacy and safety data for these drugs. The primary endpoint was the response rate based on the best overall response for up to 16 weeks. As of January 31, 2022, we included 18 drug cohorts and 295 patients were treated in this study. The most common cancer was brain tumor, followed by carcinoma of endocrine organs and colorectal cancer. BRAF mutations and ERBB2 amplifications were the frequent genomic abnormalities to be enrolled. This study was one way to access off‐label drugs, and contributed significantly to providing treatment opportunities for patients in Japan. This is a progress report of a biomarker‐based basket‐type clinical trial (NCCH1901). About 300 patients were treated in this trial and patients with BRAF mutations and ERBB2 amplifications were the frequent genomic changes to be enrolled. This trial has contributed to increasing treatment opportunities for patients in Japan.
